Applied Biosystems Introduces a New Multiplexed Reagent for Protein and Biomarker Quantitation at American Society of Mass Spectrometry
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 20, 2004--
Simplifies Proteomics and Biomarker Discovery Workflows, Reduces Time
to Critical Scientific Insights; Absolute and Relative Quantitation
Reagent Now Available in a Multiplex Format
Applied Biosystems Group (NYSE:ABI), an Applera Corporation
business, today announced the commercial availability of a new
multiplexed reagent that simplifies proteomics and biomarker discovery
workflows. The iTRAQ(TM) Reagents allow researchers to simultaneously
measure expression profiles of multiple samples, such as normal versus
diseased versus drug-treated states in a single experiment. These
reagents, for use with Applied Biosystems mass spectrometry systems,
will be introduced at the American Society for Mass Spectrometry
Conference in Nashville, Tenn., May 23-27, 2004.
With the introduction of these reagents, Applied Biosystems
expands its family of chemistries for protein identification and
quantitation. The ICAT(R) Reagents, introduced in 2001, represented
the first quantitative labeling strategy for protein expression
analysis using LC/MS approaches (ESI and MALDI) with a specific focus
on quantifying only proteins that contained the amino acid cysteine.
Using the iTRAQ(TM) reagents, researchers can now label all peptides,
leading to broader protein and proteome coverage with the ability to
detect post-translational modifications, and to compare four samples
in the same experiment. These reagents simplify the performance of
proteomics experiments, such as time course studies or expression
profiling studies for putative biomarkers.
"To elucidate even relatively simple cellular pathways,
researchers need to draw comparisons between normal versus disease
states to clearly understand up or down regulation of proteins," said
Michael W. Hunkapiller, Ph.D., President of Applied Biosystems. "With
the introduction of the iTRAQ(TM) reagents, investigators, for the
first time, can simultaneously identify and determine relative and
absolute quantity of proteins across multiple samples."
The reagents have been extensively tested at key worldwide labs,
including the University of Victoria, British Columbia, Canada, and
OSI Pharmaceuticals Inc., New York, U.S.A.
"One of the biggest advantages is the ability to analyze multiple
peptides simultaneously to gain confidence in identification and
expression values," said Robert Olafson, Ph.D., University of Victoria
and Director of the Genome BC Proteome Centre. "By running multiple
samples in a single experiment, we can expand the range of our
possible experiments while reducing our costs."
"With iTRAQ(TM) reagents, we identified a large number of
down-regulated peptides, indicating that the protein target was indeed
being influenced by our drug candidate. With the ability to compare
multiple samples in a single run, this entire process was
significantly more efficient when compared to existing technologies,"
said John Haley, Ph.D., Senior Director of Exploratory Cancer Research
at OSI Pharmaceuticals Inc.
Additionally, Applied Biosystems introduced its Pro QUANT Software
for automated analysis of LC/MS data resulting from expression
analysis with iTRAQ(TM) reagents. This software features automatic
data processing, including quantitation, protein identification and
reporting in real-time or batch mode. An integrated solution for
quantitative biology, it also provides direct access to biologically
relevant information by linking protein information with the Celera
Discovery System(TM) online platform's comprehensive, annotated
genomic database and the Panther(TM) protein database.
The iTRAQ reagents are compatible with the QSTAR(R) and Q TRAP(R)
family of LC/MS/MS systems. iTRAQ reagents and Pro QUANT Software will
become available on the Applied Biosystems 4700 Proteomics Analyzer
during summer 2004.
ASMS and Applied Biosystems Related Events
Applied Biosystems/MDS SCIEX, a joint venture between Applera
Corporation and MDS Inc., will host its annual users' meeting on
Sunday, May 23, 2004, from 9:00 a.m. - 2:30 p.m. EDT in the
Presidential Ballroom at the Gaylord Opryland Hotel in Nashville,
Tenn. Leaders from industry, as well as scientists from Applied
Biosystems, will discuss strategies for quantitating target proteins,
advances in metabolite quantitation and identification, complementary
techniques for post-translational modification analysis, and molecular
imaging with MALDI MS. Outside speakers include Richard Caprioli,
Ph.D., of Vanderbilt University. To register for users' meeting,
please visit http://info.appliedbiosystems.com/asms2004. This meeting
will not be webcast.
The iTRAQ(TM) reagents and Pro QUANT software will be discussed
and demonstrated at ASMS May 23-27, 2004, at booth number 53. Pro
QUANT software demonstrations will be given to customers and press
upon request. Applied Biosystems and its collaborators will present
data on mass spectrometry research in more than 80 scientific oral and
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied
Biosystems Group serves the life science industry and research
community by developing and marketing instrument-based systems,
consumables, software, and services. Customers use these tools to
analyze nucleic acids (DNA and RNA), small molecules, and proteins to
make scientific discoveries, develop new pharmaceuticals, and conduct
standardized testing. Applied Biosystems is headquartered in Foster
City, Calif., and reported sales of $1.7 billion during fiscal 2003.
The Celera Genomics Group (NYSE:CRA), located in Rockville, Md., and
South San Francisco, Calif., is engaged principally in integrating
advanced technologies to discover and develop new therapeutics. Celera
intends to leverage its proteomic, bioinformatic, and genomic
capabilities to identify and validate drug targets, and to discover
and develop new therapeutics. Its Celera Discovery System(TM) online
platform, marketed exclusively by Applied Biosystems, is an integrated
source of information based on the human genome and other biological
and medical sources. Celera Diagnostics, a 50/50 joint venture between
Applied Biosystems and Celera Genomics, is focused on discovery,
development, and commercialization of novel diagnostic products.
Information about Applera Corporation, including reports and other
information filed by the company with the Securities and Exchange
Commission, is available at http://www.applera.com, or by telephoning
800-762-6923. Information about Applied Biosystems is available at
Certain statements in this press release are forward-looking.
These may be identified by the use of forward-looking words or phrases
such as "believe," "expect," "plans," and "should" among others. These
forward-looking statements are based on Applera Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Applera Corporation notes
that a variety of factors could cause actual results and experience to
differ materially from the anticipated results or other expectations
expressed in such forward-looking statements. These factors include
but are not limited to (1) rapidly changing technology and dependence
on the development of new products; and (2) other factors that might
be described from time to time in Applera Corporation's filings with
the Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Applera does not
undertake any duty to update this information, including any
forward-looking statements, unless required by law.
For Research Use Only. Not for use in diagnostic procedures.
Applied Biosystems is a registered trademark and AB (Design),
Applera, Celera, Celera Diagnostics, Celera Discovery System, Celera
Genomics, iTRAQ, and Panther are trademarks of Applera Corporation and
its subsidiaries in the U.S. and/or certain other countries.
ICAT is a trademark of the University of Washington in the US and
certain other countries, licensed to the Applied Biosystems Group of
Applied Biosystems Group
Lori Murray, 650-638-6130 (Media)
Linda Greub, 650-554-2349 (Investors)
David Speechly, Ph.D., (+) 44.207.868.1642 (European
Media and Investors)
SOURCE: Applied Biosystems Group